Soleno Therapeutics, Inc. (SLNO) has been on a downward spiral lately with significant selling pressure. After declining 21.7 ...

Children were reportedly hospitalized after starting treatment. Scorpion Capital suggests Soleno's medication could face ...

H.C. Wainwright raised the firm’s price target on Soleno Therapeutics (SLNO) to $110 from $100 and keeps a Buy rating on the shares. The firm says ...

While "the trend is your friend" when it comes to short-term investing or trading, timing entries into the trend is a key ...

Soleno Therapeutics Inc (NASDAQ:SLNO) stock fell 13% Friday morning following a short report from Scorpion Capital that raised serious concerns about the company’s recently approved Prader-Willi ...

Scorpion Capital disclosed a short position in Soleno Therapeutics on Friday, citing issues with the drugmaker's recently approved treatment Vykat XR, sending its shares slumping 15% in premarket ...

SLNO is quite a good fit in this regard, gaining 52.3% over this period. However, it's not enough to look at the price change for around three months, as it doesn't reflect any trend reversal that ...

Soleno Therapeutics, Inc. SLNO will provide updates on its pipeline candidates when it releases second-quarter 2020 results. The company has a mixed track record, delivering an earnings beat in ...